Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outset Medical, Inc. (NASDAQ: OM) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Outset is a medical technology manufacturer focused on the Tablo Hemodialysis System, and its filings offer detail on financial performance, risk factors, and the business model behind its dialysis platform.
Among the key documents, investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which typically include discussions of product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and liquidity. These filings also reference the risks and uncertainties that could affect Outset’s results and the regulatory environment in which it operates.
Outset’s Form 8-K current reports are particularly relevant for tracking material events. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter financial results and updated or revised revenue guidance. Such filings summarize the nature of the event and incorporate the related press release by reference.
On this page, users can also monitor insider transaction reports on Form 4, proxy statements on Schedule 14A when available, and other submissions that shed light on governance, executive compensation, and ownership changes.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents, highlight notable changes from prior periods, and surface items such as revenue mix, margin commentary, and forward-looking statements. Real-time updates from EDGAR help ensure that new OM filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider reports, are quickly reflected and summarized for easier review.
Outset Medical, Inc. (OM)
Outset Medical, Inc. (OM) reported an insider share sale by its EVP Operations R&D & Service, Marc Nash. On 11/17/2025, Nash sold 247 shares of common stock at $4.60 per share in a transaction coded "S," leaving him with 48,268 shares beneficially owned. The company explains that the shares were sold solely to cover tax withholding obligations tied to the vesting of 674 shares of common stock underlying RSUs granted on March 15, 2023, July 24, 2023, and January 12, 2024, and that the sale did not represent a discretionary trade by Nash.
Outset Medical, Inc. reported an insider transaction by its General Counsel, John L. Brottem. On 11/17/2025, he sold 388 shares of common stock at $4.6 per share. The sale was required to cover tax withholding obligations tied to the vesting of 748 shares of common stock underlying restricted stock units granted on January 6, 2023 and January 12, 2024, and is described as a non-discretionary "sell to cover" transaction. After this trade, he directly holds 46,495 shares of Outset Medical common stock.
Outset Medical (OM) reported Q3 2025 results showing modest top-line growth and narrower losses. Revenue was $29.4 million, up slightly from $28.7 million a year ago, with product revenue of $20.6 million and service and other revenue of $8.9 million. Gross profit rose to $11.6 million as operating expenses declined, reducing the operating loss to $15.8 million. Net loss was $17.8 million, or $1.00 per share.
For the first nine months of 2025, revenue reached $90.6 million versus $84.2 million in 2024, and net loss improved to $62.2 million from $102.3 million. Cash, cash equivalents, restricted cash and short‑term investments totaled $182.0 million as of September 30, 2025. The company executed a 15‑for‑1 reverse stock split in March 2025 and completed financing steps earlier in the year, including issuing Series A convertible preferred stock that largely converted into 14,046,000 common shares at $12.00 per share and entering a $125 million term loan facility (with $100 million funded). As of November 6, 2025, shares outstanding were 18,153,090.
Outset Medical (OM)
The company notes the information is furnished under Item 2.02 and not deemed filed. The report includes forward‑looking statements and points readers to SEC filings for risk factors. Exhibit 99.1 contains the press release titled “Outset Medical Reports Third-Quarter Results.”
Marc Nash, Outset Medical's EVP, Research & Development, Operations and Services, received a grant of 5,617 restricted stock units (RSUs) on 08/25/2025. Each RSU converts to one share of common stock at no purchase price ($0.0). Following the grant, the reporting person beneficially owned 48,515 shares. The RSUs vest 33.33% on August 15, 2026, with the remaining 66.67% vesting in equal quarterly installments over the subsequent two years on each February 15, May 15, August 15 and November 15, contingent on continuous service through each vesting date.
Insider Form 4 summary: Leslie Trigg, Chair and CEO of Outset Medical, sold 904 shares of common stock on 08/15/2025 at $12.88 per share to satisfy tax withholding related to the vesting of 1,769 restricted stock units granted on January 6, 2023 and January 12, 2024. The sale is described as a "sell to cover" to meet withholding obligations and not a discretionary trade. After the transaction, Trigg beneficially owns 122,328 shares directly and 42,250 indirectly (41,666 via the Trigg 2002 Rev Trust and 584 via the Trigg Family Trust).
Marc Nash, SVP Operations and R&D and director of Outset Medical (OM), reported a non-discretionary sell-to-cover transaction on 08/15/2025. He sold 243 shares of Outset common stock at $12.88 per share to satisfy tax withholding related to the vesting of an aggregate 673 restricted stock units granted on March 15, 2023, July 24, 2023, and January 12, 2024. After the transaction, the reporting person beneficially owned 42,898 shares directly. The Form 4 was signed by John L. Brottem on behalf of Marc Nash on 08/18/2025.
This filing is a routine insider tax-withholding sale and the filer states it was not a discretionary trade.
John L. Brottem, General Counsel and director of Outset Medical, reported a routine sell-to-cover transaction on 08/15/2025. He sold 383 shares of Outset Medical common stock at $12.88 per share to satisfy tax withholding obligations arising from the vesting of 748 RSU shares awarded on January 6, 2023 and January 12, 2024. After the transaction, Brottem beneficially owned 46,883 shares directly. The filing specifies the sale was to cover taxes and was not a discretionary trade by the reporting person.
Outset Medical, Inc. insider filing reports a proposed Rule 144 sale of 904 shares of common stock via Morgan Stanley Smith Barney, with an aggregate market value of $11,643.52 and an approximate sale date of 08/15/2025. The shares were acquired the same day, 08/15/2025, as the settlement of vested restricted stock units issued as equity compensation for services rendered. The filer also disclosed a prior sale on 05/15/2025 of 935 shares for gross proceeds of $16,646.12. Outstanding common shares are listed as 17,766,193, indicating the transactions are a small fraction of total shares outstanding. The filing includes the standard attestation that the seller is not aware of undisclosed material adverse information.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
